Cargando…

Effect of Androgen Deprivation on Long-term Outcomes of Intermediate-Risk Prostate Cancer Stratified as Favorable or Unfavorable: A Secondary Analysis of the RTOG 9408 Randomized Clinical Trial

This secondary analysis of a randomized clinical trial examines the effect of androgen deprivation therapy (ADT) during radiotherapy in patients who were classified as having either favorable intermediate-risk or unfavorable intermediate-risk prostate cancer.

Detalles Bibliográficos
Autores principales:	Zumsteg, Zachary S., Spratt, Daniel E., Daskivich, Timothy J., Tighiouart, Mourad, Luu, Michael, Rodgers, Joseph P., Sandler, Howard M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2020
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489808/ https://www.ncbi.nlm.nih.gov/pubmed/32902647 http://dx.doi.org/10.1001/jamanetworkopen.2020.15083

Ejemplares similares

Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408
por: Nichols, R. Charles, et al.
Publicado: (2017)

Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial
por: Sartor, Oliver, et al.
Publicado: (2023)

Stratification of brachytherapy-treated intermediate-risk prostate cancer patients into favorable and unfavorable cohorts
por: Merrick, Gregory S., et al.
Publicado: (2015)

Oncologic Outcomes of Radical Prostatectomy and High-Dose Intensity-Modulated Radiotherapy with Androgen-Deprivation Therapy for Relatively Young Patients with Unfavorable Intermediate-Risk Prostate Adenocarcinoma
por: Wu, Szu-Yuan, et al.
Publicado: (2021)

Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
por: Amit, Uri, et al.
Publicado: (2019)

Patients’ Preferences for Androgen Deprivation Therapy in the Treatment of Intermediate-Risk Prostate Cancer
por: De, Brian, et al.
Publicado: (2022)

Granulations and Differential Diagnosis of Cases Favorable and Cases Unfavorable
por: Hinman, Thomas P.
Publicado: (1921)

Comparative effectiveness of low-dose-rate brachytherapy with or without external beam radiotherapy in favorable and unfavorable intermediate-risk prostate cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2022)

Web based pathology assessment in RTOG 98-04
por: Woodward, Wendy A, et al.
Publicado: (2014)

Stereotactic body radiotherapy versus conventional/moderate fractionated radiation therapy with androgen deprivation therapy for unfavorable risk prostate cancer
por: Patel, Sagar A., et al.
Publicado: (2020)

Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial
por: D'Amico, Anthony V., et al.
Publicado: (2021)

Favorable and unfavorable health conditions within OECD countries: An exploratory study
por: Park, Myung-Bae, et al.
Publicado: (2018)

Trends in Androgen Deprivation Use in Men With Intermediate-Risk Prostate Cancer Who Underwent Radiation Therapy
por: Agrawal, Vishesh, et al.
Publicado: (2022)

Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A systematic review and meta-analysis
por: Chen, Jiuzhou, et al.
Publicado: (2023)

Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and high-risk prostate cancer
por: Gadia, Rafael, et al.
Publicado: (2016)

Androgen deprivation therapy and Gleason grade: unravelling implications on survival
por: Scott, Michael, et al.
Publicado: (2019)

Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy
por: Stensland, Kristian D, et al.
Publicado: (2022)

Trimodal therapy with high-dose-rate brachytherapy and hypofractionated external beam radiation combined with long-term androgen deprivation for unfavorable-risk prostate cancer
por: Mori, Keiichiro, et al.
Publicado: (2021)

Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy
por: Lilleby, Wolfgang, et al.
Publicado: (2015)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial
por: Feng, Felix Y., et al.
Publicado: (2021)

Effect of RTOG breast/chest wall guidelines on dose‐volume histogram parameters
por: Rudra, Sonali, et al.
Publicado: (2014)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Androgen Deprivation Therapy and Cardiovascular Risk
por: Mourmouris, Panagiotis, et al.
Publicado: (2012)

Metabolic effects of androgen deprivation therapy
por: Choi, See Min, et al.
Publicado: (2015)

Cardiovascular Toxicities of Androgen Deprivation Therapy
por: Challa, Azariyas A., et al.
Publicado: (2021)

CARDIOVASCULAR DISEASES AND ANDROGEN DEPRIVATION THERAPY
por: Boban, Marko
Publicado: (2019)

Cardiovascular Toxicity of Androgen Deprivation Therapy
por: Boland, Julia, et al.
Publicado: (2021)

PSA-Stratified Performance of [(18)F]DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer Patients under Androgen Deprivation Therapy
por: Harsini, Sara, et al.
Publicado: (2022)

Can we avoid dose escalation for intermediate-risk prostate cancer in the setting of short-course neoadjuvant androgen deprivation?
por: Shakespeare, Thomas P, et al.
Publicado: (2016)

Do androgen deprivation and the biologically equivalent dose matter in low‐dose‐rate brachytherapy for intermediate‐risk prostate cancer?
por: Tabata, Ryuji, et al.
Publicado: (2016)

Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma
por: Schulte, Johannes H., et al.
Publicado: (2010)

Favoring the unfavored: Selective electrochemical nitrogen fixation using a reticular chemistry approach
por: Lee, Hiang Kwee, et al.
Publicado: (2018)

Differential Expression of DNA Repair Genes in Prognostically-Favorable versus Unfavorable Uveal Melanoma
por: Dogrusöz, Mehmet, et al.
Publicado: (2019)

More than Meets the Eye: Understanding Perceptions of China Beyond the Favorable–Unfavorable Dichotomy
por: Li, Xiaojun
Publicado: (2021)

Estrogen Receptor β Expression and Its Clinical Implication in Breast Cancers: Favorable or Unfavorable?
por: Choi, Young
Publicado: (2022)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
por: Chen, Mengqian, et al.
Publicado: (2010)

Impact of Androgen Deprivation on Oxidative Stress and Antioxidant Status in Nigerian Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
por: Bassey, Iya Eze, et al.
Publicado: (2020)

Clinical and dosimetric experience with MammoSite‐based brachytherapy under the RTOG 0413 protocol
por: Wojcicka, Jadwiga B., et al.
Publicado: (2007)

Differences in rates of pelvic lymph node dissection in National Comprehensive Cancer Network favorable, unfavorable intermediate- and high-risk prostate cancer across United States SEER registries
por: Flammia, Rocco Simone, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_636cd5a220nkiovkrde48au413